Resistant Social Anxiety Disorder Response to Escitalopram

Overview

Journal Clin Pract Epidemiol Ment Health

Publisher Bentham Open

Specialty Psychiatry

Date 2006 Dec 15

PMID 17166264

Citations 5

Authors

Stefano Pallanti

Leonardo Quercioli

Affiliations

Soon will be listed here.

Abstract

Background: Social Anxiety Disorder (SAD) is a common disorder and its high prevalence and lifelong chronicity are such that it represents a substantial public health problem. The observation that serotonergic agents appear to be effective for its treatment suggests that patients may have abnormal serotonergic neurotransmission within the central nervous system. We investigated the efficacy of Escitalopram in treatment resistant patients with SAD.

Method: Twenty-nine adult outpatients participated in a 12-week open-label trial of escitalopram. All the subjects had a primary diagnosis of SAD and had failed at least one previous adequate trial of paroxetine. Escitalopram was orally administered starting with a dose of 10 mg/day following a 1-week titration.

Results: The escitalopram treatment was characterized by good tolerability (drop-out rate due to intolerance: 10.3%), and 24 subjects completed the study trial. At the end of the 12-week treatment period, 14 subjects (48.3%) were considered as responders on the basis of the Clinical Global Impression-Improvement (CGI-I) (much or very much improved) scale and the Liebowitz Scale for Social Anxiety (LSAS) (reduction >35% compared to baseline). We observed a significant mean reduction in the Sheehan Disability Scale Work (p < .05) and Social (p < .05) subscores, but not in the Family subscore.

Conclusion: These data suggest escitalopram has a role in the treatment of resistant SAD, especially in view of the favourable tolerability profile observed in the patients. Controlled studies are required to further investigate these findings and to compare escitalopram with other treatments for this disorder.

Citing Articles

Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review.

Bokma W, Wetzer G, Gehrels J, Penninx B, Batelaan N, van Balkom A Depress Anxiety. 2019; 36(9):801-812.

PMID: 31231925 PMC: 6771798. DOI: 10.1002/da.22895.

Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study.

Oh K, Shin E, Ha J, Shin D, Shin Y, Lim S Clin Psychopharmacol Neurosci. 2016; 14(2):161-7.

PMID: 27121427 PMC: 4857863. DOI: 10.9758/cpn.2016.14.2.161.

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Katzman M, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M BMC Psychiatry. 2014; 14 Suppl 1:S1.

PMID: 25081580 PMC: 4120194. DOI: 10.1186/1471-244X-14-S1-S1.

Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: a randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment.

Yoshinaga N, Niitsu T, Hanaoka H, Sato Y, Ohshima F, Matsuki S BMJ Open. 2013; 3(2).

PMID: 23408078 PMC: 3586054. DOI: 10.1136/bmjopen-2012-002242.

A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder.

Stein D, Baldwin D, Bandelow B, Blanco C, Fontenelle L, Lee S Curr Psychiatry Rep. 2010; 12(5):471-7.

PMID: 20686872 DOI: 10.1007/s11920-010-0140-8.

References

Allgulander C . Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. 1999; 100(3):193-8. DOI: 10.1111/j.1600-0447.1999.tb10845.x. View

Baldwin D, Bobes J, Stein D, Scharwachter I, Faure M . Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 2000; 175:120-6. DOI: 10.1192/bjp.175.2.120. View

Lydiard R, Bobes J . Therapeutic advances: paroxetine for the treatment of social anxiety disorder. Depress Anxiety. 2000; 11(3):99-104. View

KRINGLEN E, Torgersen S, Cramer V . A Norwegian psychiatric epidemiological study. Am J Psychiatry. 2001; 158(7):1091-8. DOI: 10.1176/appi.ajp.158.7.1091. View

Varia I, Cloutier C, Doraiswamy P . Treatment of social anxiety disorder with citalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26(1):205-8. DOI: 10.1016/s0278-5846(01)00236-6. View

Spadone C . [Effects of escitalopram on anxiety symptoms in depression]. Encephale. 2002; 28(5 Pt 1):461-5. View

Atmaca M, Kuloglu M, Tezcan E, Unal A . Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002; 17(8):401-5. DOI: 10.1002/hup.436. View

Stein D, Versiani M, Hair T, Kumar R . Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry. 2002; 59(12):1111-8. DOI: 10.1001/archpsyc.59.12.1111. View

Lepola U, Loft H, Reines E . Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2003; 18(4):211-7. DOI: 10.1097/00004850-200307000-00003. View

10.

Sanchez C, Gruca P, Bien E, Papp M . R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav. 2003; 75(4):903-7. DOI: 10.1016/s0091-3057(03)00165-5. View

11.

Blanco C, Raza M, Schneier F, Liebowitz M . The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol. 2003; 6(4):427-42. DOI: 10.1017/S1461145703003791. View

12.

Shlik J, Maron E, Tru I, Aluoja A, Vasar V . Citalopram challenge in social anxiety disorder. Int J Neuropsychopharmacol. 2004; 7(2):177-82. DOI: 10.1017/S146114570300405X. View

13.

Simon N, Korbly N, Worthington J, Kinrys G, Pollack M . Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients. CNS Spectr. 2004; 7(9):655-7. DOI: 10.1017/s1092852900022148. View

14.

Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato L, van der Hoop R . Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004; 24(2):118-25. DOI: 10.1097/01.jcp.0000106222.36344.96. View

15.

Lader M, Stender K, Burger V, Nil R . Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004; 19(4):241-8. DOI: 10.1002/da.20014. View

16.

Van Ameringen M, Mancini C, Pipe B, Bennett M . Optimizing treatment in social phobia: a review of treatment resistance. CNS Spectr. 2004; 9(10):753-62. DOI: 10.1017/s1092852900022392. View

17.

Kasper S, Stein D, Loft H, Nil R . Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005; 186:222-6. DOI: 10.1192/bjp.186.3.222. View

18.

Goodman W, Bose A, Wang Q . Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005; 87(2-3):161-7. DOI: 10.1016/j.jad.2004.11.011. View

19.

Stein D, Andersen H, Goodman W . Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry. 2005; 17(2):71-5. DOI: 10.1080/10401230590932335. View

20.

El Khoury A, Gruber S, Mork A, Mathe A . Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(3):535-40. DOI: 10.1016/j.pnpbp.2005.11.011. View